Johnson & Johnson Ceases Selling Talcum Powder in the US and Canada – Update


Late last year we discussed here in Financial Regulation Matters the news that Johnson & Johnson had been ordered to pay billions of dollars in damages for the side effects that talcum powder was causing. It had been suggested at the time that the spate of litigation could end up costing the giant conglomerate more than $20 billion and, just today, the news broke that the company would cease selling the product in the US and Canada.

The talc-related saga for J&J is a long one. There has been a vast number of legal actions taken against the company, with a number of claimants being awarded large amounts, with one claim leading to $417 million in damages being awarded, and in another $4.7 billion to 22 women in the US. Interestingly Forbes said recently that J&J stock may be undervalued, but that may be about to change. The Financial Times is leading the way with the reporting that the company has dropped the sale of the product in the North American market, although they have responded as expected. Firstly, the have claimed that the cessation will not be too damaging, as the market only makes up 20% of the global market and the product will remain on sale across the rest of the world. The head of the Consumer Health division, Kathleen Widmer, was quoted in the article as blaming ‘misleading litigation advertising’ as the cause for the drop in demand of the product. The company points towards a mini-legal industry that has emerged looking for claimants, with just under 20,000 lawsuits pending against the company. The company has maintained that its product is safe, although it will now be switching to its cornstarch-based baby powder instead of the talc-based product; also, its claims that the product is widely regarded as being safe is not universally accepted.

The decision will fall into the company’s decision to ‘streamline’ its product offering in light of the COVID-19 pandemic, but in reality it will not stop the avalanche of legal action that is continuously heading its way. However, there may be an opportunity to finally switch to a non-talc based product irreversibly. Yet, the continued demand for the product around the world means that this may be some way off, unless similar legal actions are repeated in other markets.

Keywords – Talc, Johnson & Johnson, retail, business, law, @finregmatters

Comments

Post a Comment

Popular posts from this blog

Lloyds Bank and the PPI Scandal: The Premature ‘Out of the Woods’ Rhetoric

Image
Today’s very short post focuses upon the news that the Financial Conduct Authority (FCA) has recently extended the deadline to claim compensation for mis-sold ‘Payment Protection Insurance’ (PPI). Whilst a lot of financial institutions will have to prepare to offset the extended deadline, it is Lloyds that has grabbed the business headlines by apportioning an extra £350 million to offset any further claims that may be made of it – however, this comes only a week or two after the Bank posted its best performance figures in over a decade, as was previously discussed in Financial Regulation Matters . This post will therefore argue that the rhetoric being advanced recently regarding Lloyds – rhetoric like Lloyds represents ‘ a modern day success story ’ is wide of the mark and creates a false sense of security that we simply cannot afford to believe in. The ‘ robust recovery ’ was heralded far and wide upon the publication of Lloyds Bank’s financial performance for the previous fi
Read more

The Analytical Credit Rating Agency: A New Entrant That Will Further Enhance Russia’s Isolation

Image
This short post is based upon a forthcoming article by this author that examines the viability of the latest entrant into the credit rating arena, the Analytical Credit Rating Agency (ACRA). The article, which is due to be published in the European Company Law Journal (and is available here in a pre-published version), looks at the chances of the ACRA succeeding when viewed within the parameters of perception , an aspect that underpins the credit rating sector. For this post, the focus will be upon introducing the ACRA, and then on examining the effect it may have upon the wider political issues affecting the Russian Federation. The Analytical Credit Rating Agency was established in November 2015 and comprises of 27 major Russian companies and financial institutions that serve as its shareholders. The agency, which became the first rating agency to receive accreditation from the Russian Central Bank under the new N 222-FZ Law which was designed to protect investors, has a re
Read more

The Case of Purdue Pharma, the Sackler Family, and the Opioid Crisis

Image
In the first of two short posts today, we will look at the case of the billionaire Sackler Family and their remarkable effect upon American society. The family, who own Purdue Pharma amongst a list of other ventures, have this week seen a massive legal action taken against them by the State of New York who argue that the company is ‘ responsible for the opioid epidemic ’ sweeping through the United States. The attorney-general for New York has called the lawsuit the ‘ nation’s most extensive ’ with respect to the pharmaceutical industry and comes right on the heels of a $270 million suit that was settled in the State of Oklahoma on exactly the same grounds. Whilst the company and the billionaire family who own it did not admit guilt (settling parties rarely do, hence why they settle outside of court) it has potentially opened the trapdoors for litigation. It comes as no surprise then that the company is reportedly considering bankruptcy proceedings in the face of such an onsl
Read more